Kaibuchi Nobuyuki, Hoshi Keika, Yamazaki Ayame, Miyamoto-Sangu Noriko, Akagi Yuichi, Okamoto Toshihiro
Department of Oral and Maxillofacial Surgery, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University (TWIns), 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
Bone Rep. 2021 Apr 21;14:101072. doi: 10.1016/j.bonr.2021.101072. eCollection 2021 Jun.
This retrospective study aimed to examine the course and prognosis of medication-related osteonecrosis of the jaw (MRONJ) initially treated conservatively and the effects of various factors affecting treatment outcomes. We evaluated 129 patients with MRONJ between January 2008 and December 2018 at a university hospital. The factors examined included sex, age, stage of MRONJ (1-3), type of bone modifying agents (bisphosphonate or denosumab), primary disease (osteoporosis or malignant tumor), medical history (diabetes and rheumatoid arthritis), use of corticosteroids, the trigger of MRONJ (teeth extraction or others), and separation of sequestrum, using logistic regression analysis. Patients with MRONJ were treated conservatively as the initial treatment in accordance with the position paper of the American Association of Oral and Maxillofacial Surgeons. Of the 129 patients, 59 (45.7%) were cured, and the condition of 70 (54.3%) remained unchanged or worsened. The overall cure rates at 12, 36, and 60 months were 25.8%, 50.8%, and 72.4% respectively. The cure rate of stage 1 was lower than that of stages 2 and 3 at 80 months. In multivariate analysis, it was found that 37 (64.9%) of 57 patients with osteoporosis as a primary disease were cured (odds ratio [OR], 7.7; 95% confidence interval [CI], 2.4-24.4). In addition, 40 (69.0%) of 58 patients with separation of sequestrum were cured (OR, 8.9; 95% CI, 3.4-23.5). The cure rate was significantly higher in patients with osteoporosis than in those with cancer when the treatment outcomes of primary disease were compared using the Kaplan-Meier method ( < 0.01). It was also significantly higher in patients who had separation of sequestrum than in those who did not ( < 0.05). Our results suggest that primary disease and separation of sequestrum were associated with favorable outcomes in patients with MRONJ initially treated conservatively. MRONJ had a poor prognosis with conventional treatment carried according to the stage of the disease. This was especially prominent when conservative treatment was employed for mild cases.
本回顾性研究旨在探讨最初接受保守治疗的药物性颌骨坏死(MRONJ)的病程及预后,以及影响治疗结果的各种因素的作用。我们评估了2008年1月至2018年12月期间在某大学医院就诊的129例MRONJ患者。所研究的因素包括性别、年龄、MRONJ分期(1 - 3期)、骨改良剂类型(双膦酸盐或地诺单抗)、原发疾病(骨质疏松或恶性肿瘤)、病史(糖尿病和类风湿关节炎)、糖皮质激素的使用、MRONJ的触发因素(拔牙或其他)以及死骨分离情况,采用逻辑回归分析。根据美国口腔颌面外科医师协会的立场文件,MRONJ患者最初接受保守治疗。129例患者中,59例(45.7%)治愈,70例(54.3%)病情未改善或加重。12个月、36个月和60个月时的总体治愈率分别为25.8%、50.8%和72.4%。80个月时,1期的治愈率低于2期和3期。多因素分析发现,57例以骨质疏松为原发疾病的患者中有37例(64.9%)治愈(比值比[OR],7.7;95%置信区间[CI],2.4 - 24.4)。此外,58例有死骨分离的患者中有40例(69.0%)治愈(OR,8.9;95%CI,3.4 - 23.5)。当使用Kaplan - Meier方法比较原发疾病的治疗结果时,骨质疏松患者的治愈率显著高于癌症患者(<0.01)。有死骨分离的患者的治愈率也显著高于无死骨分离的患者(<0.05)。我们的结果表明,原发疾病和死骨分离与最初接受保守治疗的MRONJ患者的良好预后相关。按照疾病分期进行的传统治疗中,MRONJ的预后较差。在轻度病例采用保守治疗时尤其明显。